Biological
Bivalent Subtype C gp120/MF59
Bivalent Subtype C gp120/MF59 is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
NCT02968849
completedphase_1
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
NCT03284710
completedphase_1
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
NCT03122223
completedphase_1
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
NCT02404311
Clinical Trials (4)
Showing 4 of 4 trials
NCT02968849Phase 2
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
NCT03284710Phase 1
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
NCT03122223Phase 1
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
NCT02404311Phase 1
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4